China NMPA Inspection - Liaoning Yinyi Biotechnology Co., Ltd. - November 02, 2016

An unannounced inspection carried out by the Liaoning Provincial Food and Drug Administration revealed critical non-compliance issues at Liaoning Yinyi Biotechnology Co., Ltd. The findings, formally reported on November 2, 2016, indicated that the company's manufacturing processes and overall operational conduct failed to meet the stringent requirements outlined in the Good Manufacturing Practice for Medical Devices. A key area of concern highlighted was significant deficiencies within the company's quality management system, pointing to systemic failures in upholding regulatory benchmarks crucial for product safety and efficacy. In response to these serious observations, the Liaoning Provincial Food and Drug Administration has issued a clear directive to Liaoning Yinyi Biotechnology Co., Ltd. The company is now required to promptly implement comprehensive corrective measures to address all identified shortcomings within a defined period. This regulatory action is essential to ensure that the company's medical device manufacturing activities align fully with national quality and safety standards, thereby protecting public health. This reinforces the regulatory body's role in enforcing compliance across the industry.